Inhibitory activity of the isoflavone Biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation by Hanski, Leena et al.
RESEARCH ARTICLE
Inhibitory Activity of the Isoflavone
Biochanin A on Intracellular Bacteria of
Genus Chlamydia and Initial Development
of a Buccal Formulation
Leena Hanski1, Natalja Genina2, Hanna Uvell3, Kristina Malinovskaja4, A˚sa
Gylfe5,6,7, Timo Laaksonen4, Ruzica Kolakovic2, Ermei Ma¨kila¨8, Jarno Salonen8,
Jouni Hirvonen4, Mikael Elofsson6,7,9, Niklas Sandler2, Pia M. Vuorela1*
1. Division of Pharmaceutical Biosciences, CDR, Faculty of Pharmacy, University of Helsinki, Helsinki,
Finland, 2. Pharmaceutical Sciences Laboratory, Department of Biosciences, Abo Akademi University, Turku,
Finland, 3. Laboratories for Chemical Biology, Umea˚ University, Umea˚, Sweden, 4. Division of Pharmaceutical
Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland, 5. Department of
Clinical Microbiology, Umea˚ University, Umea˚, Sweden, 6. Umea˚ Centre for Microbial Research, Umea˚
University, Umea˚, Sweden, 7. Laboratory for Molecular Infection Medicine, Umea˚ University, Umea˚, Sweden,
8. Laboratory of Industrial Physics, Department of Physics and Astronomy, University of Turku, Turku, Finland,
9. Department of Chemistry, Umea˚ University, Umea˚, Sweden
*pia.vuorela@helsinki.fi
Abstract
Given the established role of Chlamydia spp. as causative agents of both acute and
chronic diseases, search for new antimicrobial agents against these intracellular
bacteria is required to promote human health. Isoflavones are naturally occurring
phytoestrogens, antioxidants and efflux pump inhibitors, but their therapeutic use is
limited by poor water-solubility and intense first-pass metabolism. Here, we report
on effects of isoflavones against C. pneumoniae and C. trachomatis and describe
buccal permeability and initial formulation development for biochanin A. Biochanin
A was the most potent Chlamydia growth inhibitor among the studied isoflavones,
with an IC50512 mM on C. pneumoniae inclusion counts and 6.5 mM on infectious
progeny production, both determined by immunofluorescent staining of infected
epithelial cell cultures. Encouraged by the permeation of biochanin A across
porcine buccal mucosa without detectable metabolism, oromucosal film
formulations were designed and prepared by a solvent casting method. The film
formulations showed improved dissolution rate of biochanin A compared to powder
or a physical mixture, presumably due to the solubilizing effect of hydrophilic
additives and presence of biochanin A in amorphous state. In summary, biochanin
A is a potent inhibitor of Chlamydia spp., and the in vitro dissolution results support
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the use of a buccal formulation to potentially improve its bioavailability in
antichlamydial or other pharmaceutical applications.
Introduction
Biochanin A is the main isoflavone component of red clover (Trifolium pratense
L.) and the commercially available extracts made of this plant [1]. These botanical
dietary supplements are sold in tablet form in several countries to alleviate
postmenopausal symptoms in women. In contrast to its unmethylated analogue
genistein, biochanin A is not present in soy at significant quantities, but it can be
found in many other legume plants and peanuts. The role of biochanin A and
other isoflavones in these plants is not known in detail, but generally speaking
such secondary metabolites are produced to protect the plant from radiation and
microbial attacks.
Most beneficial health effects linked to isoflavones such as biochanin A are
believed to be mediated by the estrogenic and antioxidative properties of these
compounds. Epidemiological studies have demonstrated the protective effects of
isoflavone-rich diets against breast and prostate cancer [2 and references therein],
and the affinity of isoflavones to estrogen receptors is thought to mediate also
their osteoprotective effects [3]. According to different in vitro studies, genistein is
more potent and efficient than biochanin A in terms of both estrogenic and
antioxidant activity [4, 5]. However, biochanin A is efficiently converted to
genistein during first pass metabolism, and genistein can be detected from human
plasma after ingestion of biochanin A [6].
Despite their various biological activities described in vitro and in several
animal and human studies, intake of isoflavones is known to involve a major
pharmacokinetic problem related to their poor bioavailability and significant
interpersonal variation [6, 7]. One major factor in the compromised oral
bioavailability of these compounds is their poor water-solubility; for instance
biochanin A has a reported solubility of 7 mg/ml in water [8]. Another important
contributing factor for flavonoids’ poor bioavailabilities is their extensive
metabolism and participation in enteric and enterohepatic recycling processes,
which limit their entry to systemic circulation. Due to its high permeability,
biochanin A has been shown to rapidly and efficiently penetrate into Caco-2 cells
and to be absorbed in rat intestinal perfusion models [9]. However, the absorbed
biochanin A is efficiently conjugated by different UGT and sulphatase isoforms in
enterocytes and hepatocytes and the conjugates are excreted to intestinal lumen
both directly (from the enterocytes) and indirectly (from the hepatocytes via bile
production) [9]. The conjugates can be further hydrolysed by intestinal microbes
and biochanin A and other flavonoids may thus undergo extended recycling
instead of reaching the systemic circulation.
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Besides the phase II metabolism reactions, biochanin A and other methylated
isoflavones undergo demethylation reactions in liver by phase I metabolizing
enzymes [9, 10] It has been suggested that CYP1A2 is the main cytochrome P450
isoform in human liver responsible for conversion of methylated isoflavones to
genistein and daidzein via the O-demethylation pathway as well as for the further
metabolites of genistein to 3-OH-genistein [10]. As discussed above, this is seen in
the appearance of genistein in bloodstream after oral intake of pure biochanin A,
while typically less than 5% of biochanin A is absorbed in its parent form [6].
The intracellular bacteria in family Chlamydiaceae include human pathogens
with high prevalence in both Western world and developing countries. Chlamydia
trachomatis is a sexually transmitted bacterium replicating in mucosal epithelium
and being among the most common sexually transmitted diseases worldwide [11].
Ocular C. trachomatis strains infect also conjuctival epithelial cells, which may
translate to trachoma, the most common form of preventable infectious blindness
[12]. On the other hand, C. pneumoniae is an air-borne respiratory tract pathogen
responsible for 5–10% of community acquired pneumonias and causing upper
and lower respiratory tract infections with varying severity [13, 14].
Besides epithelial cells, these unique Gram-negative bacteria can infect at least
smooth muscle cells, fibroblasts, and peripheral blood mononuclear cells (PBMC),
and particularly C. pneumoniae and C. trachomatis LGV strains have been
repeatedly isolated from body sites distant from the primary infection [15–17].
Both C. pneumoniae and C. trachomatis have been widely studied for their
propensity to convert to a persistent form of infection, which is difficult to
eradicate with currently available medication [18, 19]. Based on these and other
findings, they have been extensively discussed in the context of microbial burden
as a risk factor for several chronic diseases [20, 21].
Thus, C. pneumoniae and C. trachomatis represent Gram-negative bacteria with
major treatment challenges due to their propensity to persistence and
compromised susceptibility to first-choice antibiotics. We have previously
conducted early drug discovery applying a spectrum of different strategies with a
hypothesis that identifying novel types of small molecule inhibitors against these
pathogens provides means for more effective treatment strategies and sheds light
on the molecular details of the chlamydial infections [22–25].
In the current work, we demonstrate that biochanin A, a naturally occurring
methylated isoflavone, is a potent inhibitor of the growth of C. pneumoniae and C.
trachomatis. In an attempt to avoid the extensive first pass metabolism associated
with peroral delivery of biochanin A, permeation through porcine buccal mucosa
was studied and different film formulations for buccal delivery were developed
and investigated with regard to their solid-state characteristics and in vitro
dissolution rates.
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Materials and Methods
Materials
Biochanin A, formononetin, genistein, daidzein, genistin and daidzin (Fig. 1)
were purchased from Sigma-Aldrich, (St. Louis, MO, USA) and dissolved in
dimethyl sulfoxide (DMSO) for the biological experiments. The purity of the
compounds were .98.0%. For formulation studies, biochanin A was dissolved in
ethanol. Rifampicin used as a positive control in experiments with C. pneumoniae
was from Fluka (Buchs, Switzerland) and was dissolved in ethanol.
Hydroxypropyl cellulose (HPC, Klucel LF), crospovidone and sodium starch
glycolate were provided by Astra Zeneca, Sweden. Hydroxypropyl methylcellulose
(HPMC, Metolose 90SH-4000) and sodium dodecyl sulfate (SDS, Fluka
Biochemika) were purchased from Japan. Polyvinylpyrrolidone (PVP, K-30,
Mr,40000, Switzerland) and Tween 20 were obtained from Fluka Chemicals.
Maize starch (C*Gel, Cargill) was obtained from Segerha. Propylene glycol (PG)
was purchased from Germany. A flavoring agent levomenthol was obtained from
Yliopiston Apteekki, Finland. All other chemicals and solvents used were of
analytical grade.
Cell culture and Chlamydia stocks
Human epithelial HL cells of respiratory tract origin [26] were grown in RPMI
1640 (BioWhittaker, Lonza, Basel, Switzerland), supplemented with 7.5% fetal
bovine serum (FBS) (BioWhittaker, Lonza, Basel, Switzerland), 2 mM L-
glutamine (BioWhittaker, Lonza, Basel, Switzerland) and 20 mg/ml of gentamicin
(Fluka, Buchs, Switzerland). HeLa-229 cells (CCL-2.1; ATCC, Manassas, VA,
USA) were maintained in RPMI1640 supplemented with 20 mM HEPES
(pH 8.0), 10% FBS, 2 mM L-glutamine, 8 mg/ml gentamicin and 1 mg/ml
amphotericin B. The cells were cultured in standard cell culture protocols at 37 C˚
and 5% CO2. For all infections with C. pneumoniae, HL cells were seeded into 24-
well plates with coverslips at density 46105 cells per well and incubated overnight
before used for infection.
The C. pneumoniae clinical isolate K7 [27] was propagated as described in
Alvesalo et al. [23] and stored in SPG buffer in 270 C˚. C. trachomatis serovars K
(VR-887, ATCC) and L2 (VR-902B; ATCC) were propagated in HeLa 229 cells
and handled as described in [28].
Infections
C. pneumoniae infections in HL cells were carried out by diluting the bacterium in
the HL cell growth medium supplemented with 1 mg/ml cycloheximide (Sigma-
Aldrich, St. Louis, MO, USA) and inoculating HL cell monolayers with the
multiplicity of infection (MOI) 0.2. After inoculation, the plates were centrifuged
at 5506g for 1 h at 4 C˚ and then incubated at 37 C˚ for 1 h. Then the inocula were
removed and fresh medium with assayed compounds or solvent control (DMSO
0.2–0.5% depending on experiment) was added. At 72 h post infection, the wells
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were washed with PBS and the coverslips were fixed with methanol. The staining
of host cells and chlamydia inclusions was carried out using Pathfinder Chlamydia
Culture Confirmation System reagent (Bio-Rad, Hercules, CA, USA) and the
inclusion counts were determined under fluorescent microscope. Chlamydia
trachomatis infections in HeLa-229 cells were done essentially as described in [28],
with the following exceptions; the concentrations tested were 100, 75, 50, 25, 10, 5
and 2.5 mM and the HeLa cells were infected 18 h before fixation and
immunostaining. The immunostainings were analyzed using an ArrayScanVTI
HCA reader (Thermo Fisher Scientific Inc., USA). Rifampicin was used as a
positive control in the infections, consistently yielding 95–98% reduction in
inclusion counts at concentration 12 nM.
Infectious progeny assay
To assay the effect of the compounds on the production of infectious progeny, HL
cells were infected with C. pneumoniae and treated with the compounds as
described above. At 72 h, two coverslips were fixed and stained as described above
to confirm the infectivity and inhibitory effects of the compound. In another two
wells medium was removed, 200 ml fresh medium was added and cells were
scraped off and ruptured by vortexing with glass beads. The solution was used to
infect fresh monolayers of HL cells seeded the day before. At 144 h, the cultures
with the second passage infections were fixed and stained as described above.
Pretreatment experiments
For Chlamydial elementary body (EB) pretreatment experiments, C. pneumoniae
stocks were diluted in the infection medium and biochanin A was added in
Fig. 1. Chemical structures of the six isoflavones included in the study.
doi:10.1371/journal.pone.0115115.g001
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aliquots of the diluted EB suspension. The suspension was incubated at 4 C˚ for
1 h and was then used to infect HL cells as described above. For host cells
pretreatment experiments, HL cells seeded in 24-well plates were incubated in the
presence of biochanin A at 37 C˚ for 1 h. Then, the samples were removed, the cell
monolayers were washed once with infection medium and infected with C.
pneumoniae as described above.
Cell viability assays
HL and HeLa cells were seeded into 96-well plates at density 66105 cells per well
and incubated overnight before exposed to the compounds in various
concentrations for 72 h. The medium was removed after the exposure period and
20 mM resazurin solution in PBS was added into the wells. The plates were
incubated for 2 h at 37 C˚ and the fluorescence was recorded at 570/590 nm (ex/
em).
Preparation of buccal films and physical mixture
Buccal films of water-soluble polymers HPC and HPMC were prepared by solvent
casting method. HPC-containing films were prepared using ethanol as a solvent,
whereas HPMC films were prepared from aqueous-alcoholic solutions. The
composition of different formulations is presented in Table 1. Alcoholic and
aqueous solutions were prepared by dissolving the polymer (%w/w) and the
plastisizer in the solvent and allowing it to stir for 2 h. After that all excipients
were added (except for formulations Fjj, Fkk, Fll) and the solutions/suspensions
were stirred for 2 h. When the maize starch was used (Fbb, Fjj, Fkk and Fll), the
suspension was heated above the gelation point of starch (64 C˚) at 70 C˚ for
30 min and after that continued stirring for 1.5 h. The amount of 5 mg/ml
biochanin A powder (except for Fii) was added to all formulations. Formulation
Fii was prepared by first dissolving biochanin A into pure alcohol and then adding
2% HPMC aqueous solution to get 5 mg/ml biochanin formulation. In addition,
formulations containing 2.5 mg/ml and 10 mg/ml biochanin A were prepared
(composition corresponding to formulation Faa). In the case, when solubilizers
were used (Fjj, Fkk, Fll), biochanin A was first premixed with them and after that
the liquid formulations were added aiming to prepare 5 mg/ml mixtures. The
biochanin A-containing preparations were stirred until the isoflavone was
dissolved. After that the formulations were kept unstirred for 0.5 h to remove all
the bubbles entrapped. The formulations were cast onto intermediate liners
(DatalineTM Transparency film, code 57167, EU) with 1 ml of the formulation
per 10 cm2 of the liner, with the aim to produce 4 cm2 cut squares (262 cm)
containing 2 mg of the drug in each. The films were left to dry in ambient
conditions (relative humidity 45¡5%, temperature 22¡2 C˚) for 12 h. The
produced films were stored in tightly closed folium envelopes until further
analysis. The physical mixtures corresponding to formulation Faa were prepared
by using spatula and mortar before analysis.
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In vitro dissolution studies
The dissolution testing was performed according to the USP paddle method by
using the Sotax AT7 Smart dissolution tester (SOTAX, Switzerland) and UV/Vis
spectrophotometer (PerkinElmer, Lambda 25, USA) at 261 nm. In order to
maintain sink conditions and mimic the pH of saliva, the dissolution experiments
were carried out in 900 ml of phosphate buffer at pH 6.8 (0.1 M NaH2PO4?H2O
and Na2HPO4?2H2O in water) at rotation speed of 100 rpm and temperature of
37¡0.5 C˚. The films of,4 cm2 were put into the spiral capsule sinkers to prevent
floating. Powder and physical mixture were immersed into the dissolution media
at concentration, corresponding to 2 mg of biochanin A per vessel.
Thickness
The thickness of each film was measured using a Digimatic caliper (AbsoluteTM
Digimatic, Mitutoya Corporation, Kawasaki, Japan) at four locations.
Optical microscopy
Optical microscopy (OM, Evos XL, AMG, USA) in connection with a digital
camera (DC) was used to visualize the samples at magnifications of 46 and 406.
Folding endurance
Folding endurance was determined by bending the films at the same place until it
broke. The number of times the films folded without breaking was counted.
Table 1. Composition of sublingual films of biochanin A.
Ingredients Faa Fbb Fdd Fee Fii Fjj Fkk Fll
Biochanin A (mg/ml) 5 5 5 5 5 5 5 5
HPC (%w/w) 5 5 5 5 — 5 5 5
HPMC (%w/w) — — — — 1 — — —
PVP, K-30** — — — — — — — 1:2
SDS** — — — — — — 1:2 —
Tween 20** — — — — — 1:2 — —
Crospovidone* — — — 16.7 — — — —
Na starch glycolate* — — 16.7 — — — — —
Maize starch* — 16.7 — — — 16.7 16.7 16.7
Propylene glycol (PG)* 6.3 6.3 6.3 6.3 5.9 6.3 6.3 6.3
Levomenthol* — — — — — 0.7 0.7 0.7
*Quantities are expressed in %w/w of polymer; **Quantities are expressed in ratio of biochanin A to excipient.
doi:10.1371/journal.pone.0115115.t001
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X-ray diffraction (XRD)
The X-ray diffraction patterns of the film samples were measured with an X-ray
diffractometer (Philips, X’Pert PRO MPD, Holland). Measurements were
performed in h/2h Bragg-Bretano geometry with Cu Ka radiation (l51.54 A˚).
The range measured was 3–40˚ with steps of 0.04˚ (time per step 2 s) using a
voltage of 40 kV and a current of 50 mA.
Thermal analysis
Weight loss was determined by thermogravimetric analysis, using STA 6000
Simultaneous Thermal Analyzer (PerkinElmer Instruments, USA). Samples of 4–
5 mg were analyzed at the heating rate of 20 C˚/min with the temperature range of
25–900 C˚. A N2 purge with a flow rate of 40 ml/min was used in the furnace.
Differential scanning calorimetry (DSC) was carried out with PYRIS Diamond
DSC (PerkinElmer Instruments, USA). 30 ml aluminum pans with pierced lids
were used to analyze samples of 1–3 mg. The heating rate of the samples was 10 C˚
min21, and the flow rate of N2 purge was 40 ml/min. Indium (156.60 C˚) was used
to calibrate DSC system.
High-performance liquid chromatography (HPLC)
Biochanin A and genistein were analyzed by HPLC (Hewlett Packard Series II
1090 LC instrument) from film formulations as samples of 4 cm2 in 25 ml of
ethanol, using Inertsil ODS-3 5 mm, 15064.0 mm + Security Guard Cartridge Kit
(C18) 2.064.0 mm at 40 C˚. Biochanin A and genistein concentrations in buccal
permeation experiments were analyzed by HPLC instrument Agilent 1100 Series
(Agilent Technologies, Germany), using Discovery C18 5 mm, 15064.6 mm
column (Supelco Analytical, PA, USA) at 40 C˚. Biochanin A and genistein were
determined by using slightly modified methods as presented by Han et al. [8] and
Krenn et al. [29]. The eluent consisted of water adjusted with sulphuric acid to
pH 2.7 and acetonitrile (58:42 v/v%). The flow rate was 1.0 ml/min and the
wavelength of detection was set at 254 nm. The injection volume of the samples
was 10 ml. The retention times of biochanin A and genistein were 9.2 and 3.7 min,
respectively. The linear concentration range of both compounds was established
in the range of 0.1–100 mg/ml (R250.9999).
Solubility analysis
To determine the solubility of biochanin A in ethanol, 20 mg of powder was
added into 1 ml of ethanol and stirred at 700 rpm for 24 h at 37 C˚ by using a
Thermo shaker (BioSan, PST-100HL). The sample was centrifuged at 13000 rpm
for 10 min and the supernatant was filtered (VWR, 0.2 mm pore-sized cellulose
acetate sterile syringe filter), diluted and analysed for biochanin A content by
using UV/Vis spectrophotometer (PerkinElmer, Lambda 25, USA).
Antichlamydial Activity and Formulation of Biochanin A
PLOS ONE | DOI:10.1371/journal.pone.0115115 December 16, 2014 8 / 27
Permeability across buccal mucosa
Pig cheeks were obtained from a local abattoir within a few hours postmortem.
Buccal mucosa was carefully separated from the muscle tissue with surgical
scissors and stored at 220 C˚ until further use. In vitro permeation studies of
biochanin A from solution or film formulations were performed in Side-by-side-
diffusion cells (Laborexin, Helsinki, Finland) or Franz diffusion cells (PermeGear
Inc., PA, USA), respectively. Pieces of porcine full-thickness buccal mucosa were
clamped between two halves of diffusion cells. The area of mucosa was 0.785 cm2
or 0.503 cm2 in studies with Side-by-side or Franz diffusion cells, respectively. To
mimic physiological conditions, the cells were thermostated at 37 C˚ by a
surrounding socket or an incubator.
In studies with solutions, 3 ml of 1 mg/ml biochanin A solution in 0.1 M
phosphate buffer (pH56.8) including 40% of DMSO was placed in the donor
compartment of the diffusion cells. The same buffer was used in the receiver
compartment, whose volume was 3 ml. 300 ml samples for HPLC analysis were
collected from the receiver compartment and replaced by fresh buffer at 0.5, 1, 2,
3, 4, 5 and 6 h. In studies with films, 0.5 ml of 0.1 M phosphate buffer (pH56.8)
was placed in the donor compartment of the diffusion cells to wet the buccal
mucosa and the film (containing 2 mg of biochanin A). The same buffer was used
in the receiver compartment, whose volume was 5 ml. After 4 h, both solutions
were replaced with a phosphate buffer including 20% DMSO. 200 ml samples for
HPLC analysis were collected from the receiver compartment and replaced by
fresh medium at each time point.
Data analysis
Unless otherwise stated in the text, all experiments were carried out as at least
three replicates and results were expressed as mean and standard deviation. All
further analyses, including linear regression analysis on the data from dose-
response experiments and statistical testing was carried out using GraphPad Prism
4.0. software.
Ethics
Pig cheeks used to supply the buccal tissue for permeability studies were obtained
from a local abattoir from the material left unused within food production (HK
Ruokatalo, Mellila¨, Finland). No animals were specifically sacrificed for the needs
of the study.
Results
Antichlamydial activity of isoflavones
Using a recently described high-content screening platform [30], biochanin A was
identified as a hit from in-house library of 2000 compounds in our screen for
antichlamydial compounds. In preliminary experiments with C. pneumoniae
Antichlamydial Activity and Formulation of Biochanin A
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infections in human epithelial HL cells, no chlamydial inclusions were detectable
in infected cultures treated with 50 mM biochanin A, indicating that biochanin A
was able to completely block C. pneumoniae replication at this concentration.
Experiments conducted using serial dilutions of biochanin A demonstrated a
dose-dependent inhibition of C. pneumoniae inclusion counts, showing an IC50
value (the concentration yielding 50% of the inclusion counts compared to the
untreated infection) of 12 mM (Table 2).
Our earlier studies have indicated that isoflavones genistein and daidzein are
able to moderately suppress C. pneumoniae replication while the corresponding
glycosides genistin and daidzin are not active at 50 mM [23]. Biochanin A differs
chemically from genistein only by methylation of one hydroxyl group (Fig. 1) but
this subtle change in the chemical structure resulted in a significant improvement
in anti-C. pneumoniae activity. This feature was confirmed in re-testing of
biochanin A and the four isoflavones reported in Alvesalo et al. [23] against C.
pneumoniae (Table 2) and is also illustrated by the fact that none of the four
previously studied isoflavones exceeded the hit limit even though they had been
included in our screen together with biochanin A. As the current data suggested
that methylation of the hydroxyl group improved the antichlamydial activity, we
studied also formononetin, the corresponding methylated derivative of daidzein,
which is also the other main isoflavone found in red clover [1]. The IC50 values
presented in Table 2 demonstrate that biochanin A and formononetin are more
potent in decreasing C. pneumoniae inclusion counts than their unmethylated
analogues genistein and daidzein. However, also the hydroxyl group in position 7
(present in biochanin A and genistein but absent in formononetin and daidzein)
contributes to the antichlamydial activity as can be observed from pairwise
comparison of the IC50 values.
Despite being members of the same taxonomical family, significant differences
in susceptibility are known to exist between different Chlamydia spp. The effects
of these six isoflavones were also investigated on C. trachomatis. As shown by the
results presented in Table 2, biochanin A was the most potent of these
compounds in decreasing C. trachomatis serovar L2 inclusion counts, followed by
genistein, while formononetin and daidzein were not able to decrease C.
trachomatis inclusion counts with any of the concentrations tested (up to
100 mM). A similar activity pattern was observed also against C. trachomatis
serovar K (data not shown). However, daidzein was able to moderately decrease
the average C. trachomatis inclusion size at high concentrations while
formononetin did not show antichlamydial effects even in this respect (Fig. 2).
Biochanin A and genistein were significantly more active in decreasing inclusion
sizes than daidzein, thus emphasizing the essential role of 7-hydroxyl substitution
in the activity against C. trachomatis.
Taken together, biochanin A was the most efficient antichlamydial compound
among the studied isoflavones. Cell viability assays conducted with resazurin
reduction test confirmed that none of the six isoflavones assayed in this study
decreased host cell (HL or HeLa) viability when applied in the same
concentrations and exposure times as used for the antichlamydial assays (data not
Antichlamydial Activity and Formulation of Biochanin A
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shown). Biochanin A was additionally assayed in different concentrations up to
500 mM on HL cells but no signs of decreased cell viability upon 72 h exposure
were observed.
Table 2. IC50 values (mM) of isoflavones on C. pneumoniae and C. trachomatis inclusion counts.
Compound C. pneumoniae IC50 (mM)* C. trachomatis IC50 (mM)*
Biochanin A 12¡5 62¡9
Genistein 64¡8 79¡10
Genistin .100 .100
Formononetin 53¡10 -
Daidzein 87¡12 -
Daidzin .100 .100
*IC50 values were determined by treating the infected cell cultures with isoflavones at concentration 100, 75, 50, 25, 10 and 5 mM and determining the
inclusion counts as described in Materials and methods. - 5 no inhibition. A statistically significant difference in C. pneumoniae IC50 values was observed
between biochanin A and genistein (p,0.05, Student’s t-test)
doi:10.1371/journal.pone.0115115.t002
Fig. 2. Effect of isoflavones on C. trachomatis inclusion size. A) Immunofluorescence images of C. trachomatis infected HeLa cells (untreated and
treated with 100 or 10 mM biochanin A). Chlamydia inclusions are stained in green (polyclonal rabbit antibody raised against formalin fixed C. trachomatis
elementary bodies [30]) and host cell nuclei are stained in blue with DAPI. B) Quantitation of average inclusion sizes in C. trachomatis infections treated with
the isoflavones. Inclusion sizes are expressed as relative units proportional to the untreated controls. In a pairwise comparison of different concentrations,
the mean inclusion size in biochanin A, genistein and genistin treated samples were statistically significantly smaller than in formononetin, daidzein and
daidzin treated samples, respectively (p,0.05, Student’s t-test).
doi:10.1371/journal.pone.0115115.g002
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Biochanin A as antichlamydial compound
As the data presented above demonstrated that biochanin A is able to decrease C.
pneumoniae and C. trachomatis infectivity measured as inclusion counts in
infected cell cultures, we further characterized this isoflavone for its properties as
Chlamydia growth inhibitor by an infectious progeny assay. Here, HL cells
infected with C. pneumoniae were treated with biochanin A in concentrations
ranging from 2.5 to 50 mM. At 72 h, lysates of the cultures were collected and used
for infecting fresh HL cell monolayers to evaluate the number of infectious EBs
produced in the biochanin A-treated cultures. As shown by the dose-response
curves presented in Fig. 3A, production of infectious progeny EBs was efficiently
inhibited by biochanin A and an IC50 value of 6.5 mM was achieved.
As obligate intracellular bacteria, Chlamydia have a unique biphasic replication
cycle involving successive conversion between the elementary body (EB), the
extracellular, infectious but nonreplicating form, and the reticulate body (RB), the
intracellular replicating form [31]. Upon entry of an EB into its host cell, the
complete life cycle resulting in the release of mature progeny EBs takes typically
72 h for C. pneumoniae in laboratory conditions, while most C. trachomatis
strains can complete their life cycle in cell culture within 48 h. In standard
antichlamydial assays with C. pneumoniae, the assayed compounds are added into
infected cultures at 2 h post infection, i.e. when the bacterial inocula are removed
from the wells. In order to further characterize effect of biochanin A on C.
pneumoniae, a series of pretreatment and delayed administration time experi-
ments were conducted.
Treatment of C. pneumoniae EBs with 50 or 25 mM biochanin A before using
the EBs for inoculation did not have any significant effect on inclusion counts,
indicating that biochanin A does not have a direct effect on this form of the
bacterium (Fig. 3B, right). On the other hand, treating the HL cell monolayers
with 50 mM biochanin A for 1 h prior to inoculation resulted in approximately
30% decrease in C. pneumoniae inclusion counts even though biochanin A was
not added into the inoculation medium (Fig. 3B, left). This finding is in
accordance with our earlier observation that pretreatment of HL cells with some
flavonoids prior to C. pneumoniae infection decreases inclusion count even when
the flavonoid is not added into the culture medium during the infection [23].
Flavonoids are known to accumulate to and interact with biological membranes
[32], but the concentration of the remaining compound fraction after changing
the medium is difficult to estimate.
In delayed administration time experiments, biochanin A (50 mM) was added
into the culture medium at different time points post infection. Adding the
compound to the infection medium according to the standard procedure
immediately after the removal of inocula (2 h post infection) confirmed the 100%
inhibition on inclusion counts and infectious progeny production by 50 mM
biochanin A (Fig. 3C). Complete inhibition of inclusion formation and infectious
progeny production was also observed when biochanin A was incorporated into
the infected cultures at 6 or 12 h post infection, while adding the compound at
24 h reduced the number of visible inclusions by 47% and infectious progeny
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Fig. 3. Impact of biochanin A on C. pneumoniae replication. A) Inhibition of C. pneumoniae inclusion
counts and infectious progeny production by different concentrations of biochanin A. B) Effect of host cell or
elementary body (EB) pretreatment with biochanin A on C. pneumoniae inclusion counts. C) Effect of delayed
administration of biochanin A on the inhibitory capacity of biochanin A on C. pneumoniae inclusion counts (1st
passage) and infectious progeny production (2nd passage). Biochanin A (50 mM) was added into infected cell
cultures at 2, 6, 12 or 24 h post infection. In all experiments, the cultures were stained at 72 h as described in
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production by 62%. Furthermore, the inclusions seen in 24 h administration
sample appeared significantly smaller than inclusions in the untreated control
infections, indicating suppression of replicating bacteria in the inclusions. A
similar activity pattern was observed also with C. trachomatis serovar K. Thus the
antichlamydial activity of biochanin A is not limited to any specific step occurring
early in the infectious cycle but rather the compound maintains its activity also in
cases where the bacterium has already established its replicative machinery within
the host cell.
Permeability of biochanin A across buccal mucosa
Since our data indicated that already small chemical modifications seemed to have
a remarkable impact on the antichlamydial activities of the related flavonoids, it
was necessary to find an alternative route of administering biochanin A and avoid
the demethylation reaction occurring during first pass metabolism. For this
purpose, permeability of biochanin A across buccal mucosa was studied in a
diffusion cell system using porcine buccal mucosa preparations. When biochanin
A was added as 1 mg/ml in the donor compartment, 19.37¡3.34 mg biochanin A
was delivered across buccal mucosa per cm2 of tissue into receiver compartments
in 6 h (Fig. 4). A steady-state flux of biochanin A was attained in three hours and
the lag-time was 132 min. The steady-state flux was 5.00¡0.83 mg/h?cm2. No
detectable genistein peaks were observed in receiver compartment samples during
6 h of the permeation study. Furthermore, it has to be noted that in order to
achieve HPLC-detectable amount of the permeated drug, the 1 mg/ml
concentration of biochanin A in donor compartment was achieved by addition of
DMSO. Even though the amount of biochanin A passed through in these
conditions was rather small, the data showed a significant improvement compared
to the intestinal bioavailability reports as demethylation did not occur.
Preparation of buccal dosage forms
Encouraged by the lack of demethylation reactions during biochanin A
permeation through buccal mucosa, it became feasible to look for suitable
formulation for buccal administration. To this end, biochanin A containing
buccal dosage forms were prepared by using two different film forming polymers:
hydroxypropyl cellulose (HPC) and hydroxypropyl methylcellulose (HPMC)
(Table 1). HPC is soluble both in water and ethanol, whereas HPMC is insoluble
in pure ethanol, but soluble in ethanol-water mixtures. Biochanin A solubility in
ethanol was determined to be 15 mg/ml which is more than 2000 times higher
than the reported water solubility of this compound (7 mg/ml; [8]). Based on this,
Materials and Methods. *** In B) and C) indicates statistically significant difference (p,0.05; unpaired t-test)
compared to untreated control infection.
doi:10.1371/journal.pone.0115115.g003
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HPC was considered as the first-choice polymer to produce buccal films of
different compositions from alcoholic polymer solutions or suspensions.
To improve film flexibility and reduce their brittleness, selection of a suitable
plasticizer among the most commonly used ones (glycerol; propylene glycol, PG)
and polyethylene glycol (PEG 400) was needed. Based on literature, HPC is
soluble in PG and PEG 400, but insoluble in glycerol [33]. Based on the
experiments conducted with PG and PEG, PG was chosen as plasticizer for the
films, as films produced with PEG 400 were too soft. In addition, a disintegrant
was selected with the aim to increase the release rate of biochanin A from the strip.
Two superdisintegrants with different mechanisms of action, crospovidone and
sodium starch glycolate, were studied for this purpose. In addition, maize starch
was tested as disintegrant and hydrophilic bulking agent. Because these excipients
are insoluble in cold water and ethanol; they were suspended in the film forming
formulations. To further improve the bioavailability of biochanin A, different
solubilizing agents such as nonionic PVP K30 and Tween 20, and anionic SDS
were included in the film composition. Furthermore, L-menthol was used as a
flavoring agent and odor enhancer due to its cooling sensation and peppermint
taste.
The characteristics of the produced strips are presented in Table 3. The primary
acceptance criteria for the prepared buccal films of different formulations were
homogeneous appearance, ease of detachment from the intermediate liner,
minimal stickiness and brittleness. Formulations containing SDS or PVP K30 as
solubilizers (formulations Fkk and Fll) did not produce a detachable film.
Different ratios of biochanin A to the solubilizers were studied, but none of these
films prepared possessed proper characteristics. However, the other formulations
gave films with acceptable properties (Fig. 5). The appearance of the produced
strips containing biochanin A was similar to blank strips prepared without the
API, except for formulation Fii (Fig. 5). In the cases when the casting
formulations were of suspension type, the particles of the disintegrants could be
observed with the naked eye (Fbb, Fdd, Fee, Fjj). Formulations Fbb, Fdd, Fee, and
Fjj were stiffer than formulations Faa and Fii. The films produced from
Fig. 4. Permeability of biochanin A across porcine buccal mucosa. Cumulative amount of biochanin A
was measured from the acceptor compartment of the diffusion cell.
doi:10.1371/journal.pone.0115115.g004
Antichlamydial Activity and Formulation of Biochanin A
PLOS ONE | DOI:10.1371/journal.pone.0115115 December 16, 2014 15 / 27
formulation Fii were totally matt if compared to the transparent blank film.
Precipitation of biochanin A occurred, when the compound dissolved in ethanol
was mixed with the aqueous HPMC solution as it was practically insoluble in
water.
Stability of biochanin A during formulation
The potential conversion of biochanin A to genistein in the prepared films was
studied to ensure the release of the correct API from the formulations. An attempt
to detect genistein in biochanin A powder and films prepared from biochanin A
was made by using thermal analysis (S1 Figure). STA thermograms of biochanin A
revealed the melting point at 212 C˚ with subsequent degradation, whereas
genistein showed the endothermic event at 303 C˚ with further degradation. Thus,
Table 3. Properties of sublingual films of biochanin A. Data are presented as mean ¡ standard deviation (an512 and bn53–4).
Form Appearance aThickness (mm) bFolding endurance bWeight (mg/4 cm2)
Faa Transparent, pale yellow, smooth surface, easy to detach 53¡28 .500 16.5¡1.3
Fbb Slightly matt, pale yellow, easy to detach, rough surface, the
lines of undissolved starch could be seen
66¡32 .500 20.4¡2.8
Fdd Slightly matt, pale yellow, not so easy to detach, rough
surface, the lines of undissolved disintergrant could be seen
57¡27 .500 19.5¡2.4
Fee Slightly matt, pale yellow, easy to detach, rough surface, the
lines of undissolved disintergrant could be seen
84¡19 .500 21.4¡2.7
Fii Matt, pale yellow, smooth surface, easy to detach, produces
cellophane noise during folding/bending
10¡1 .500 5.9¡0.5
Fjj Slightly matt, pale yellow, easily detachable, the lines of
undissolved starch could be seen
73¡31 223¡30 23.8¡2.4
Fkk Slightly matt, pale yellow, ductile, impossible to detach, the
lines of undissolved starch could be seen
— — —
Fll* Slightly matt, pale yellow, brittle, difficult-to-impossible to
detach, the lines of undissolved starch could be seen
68¡25 — —
*analysis was done with small parts of the film (n54).
doi:10.1371/journal.pone.0115115.t003
Fig. 5. Optical microscope images of the film formulations. Top view: blank films (A–F), bottom view: Biochanin A containing films (G–L). Formulations:
Faa (A,G), Fbb (B,H), Fdd (C, I), Fee (D, J), Fii (E,K) and Fjj (F,L) at magnification 40x.
doi:10.1371/journal.pone.0115115.g005
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the presence of genistein in biochanin A containing formulation cannot be
detected by STA, since biochanin A starts its degradation before the melting peak
of genistein appears.
As an alternative approach, HPLC analysis was conducted to detect any traces
of genistein in the biochanin A powder and the formulation Faa. Biochanin A
powder contained less than 0.8% of genistein. The HPLC analysis of the film
(formulation Faa) showed that the drug is present as biochanin A with the same
percent of genistein as the pure powder (S1 Table).
In vitro dissolution
The release profiles of biochanin A from the prepared films, physical mixture and
the pure powder are presented in Fig. 6. The amount of dissolved biochanin A
powder was negligible, less than 2% in 4 h. The physical mixture of formulation
Faa showed improved dissolution rate of biochanin A: 16% drug was released in
4 h. There was a drastic increase in the percent drug released by using a film of the
same formulation (Faa): as more than 90% of the compound was released in 4 h.
Dissolving biochanin A in the polymer-containing alcoholic solution before
casting the strip gave rise to the production of the solid type films with improved
dissolution characteristics. The improved bioavailability of some poorly soluble
drugs from film preparations has been previously reported by other researches
[34, 35]. However, the drug release from the film containing no solubilizers or
disintegrants (formulation Faa) was relatively slow and incomplete. Considering
the disintegrants crospovidone and sodium starch glycolate (formulations Fdd
and Fee) did not affect the dissolution profile of biochanin A significantly. The
addition of maize starch (formulation Fee) caused the complete release of
biochanin A from the film in 4 h. Inclusion of Tween 20 as a solubilizer in the film
formulation along with maize starch (formulation Fjj) fastened further the
dissolution of biochanin A and caused complete release of the API. The release of
biochanin A from the films made of HPMC instead of HPC (formulation Fii) was
the slowest and incomplete due to partial recrystallization of biochanin A during
film preparation as mentioned above. Additionally, the amount of HPMC present
in the film was five times smaller than the HPC amount in the other films, due to
the highest viscosity grade of the HPMC powder used. Solutions with higher
HPMC concentrations were also tested but they were found to be difficult to
prepare and almost impossible to cast uniformly. It is evident that adequate
solubilisation of biochanin A is needed to guarantee fast release of it from the
solid formulation.
To classify the films between immediate- or controlled-release formulations, the
film of formulation Fjj (HPC containing maize starch and Tween 20) is of
immediate-release type solid dosage form as it released 85% of biochanin A in less
than 45 min. The films with other formulations can be regarded as modified-
release solid dosage forms.
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Permeation of biochanin A released from the films across buccal
mucosa
Buccal mucosa permeability studies were also extended on biochanin A released
from Fjj films, indicating a behavior consistent with the earlier permeability data.
When dissolved in phosphate buffer, no biochanin A had permeated across the
buccal mucosa after 4 h. The medium was then changed to a buffer with 20%
DMSO in order to increase the solubility of biochanin A in the medium and
therefore to increase its flux across the mucosa. In 20 h in the new buffer
21.19¡4.74 mg biochanin A was delivered across buccal mucosa per cm2 of tissue
Fig. 6. Dissolution profiles of biochanin A from buccal films of different composition, physical mixture
(PM, corresponding to formulation Faa) and powder at pH 6.8. Data are presented as mean¡ standard
deviation (n53).
doi:10.1371/journal.pone.0115115.g006
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into receiver compartments of the Franz cells. A steady-state flux of biochanin A
was attained in one hour after introducing DMSO into the system. The steady-
state flux was 1.10¡0.26 mg/h?cm2. No detectable degradation peaks (genistein or
other) were observed in receiver compartment samples during the permeation
study.
Solid state characterization
As indicated by the optical microscope images in Fig. 5, biochanin A powder is a
crystalline material. To study the physical state of biochanin A in the films, X-ray
diffractograms were collected from samples with different formulation. The X-ray
diffractograms of the film formulations Faa and Fjj showed a halo pattern, while
biochanin A-related peaks were observed from the samples of physical mixture
and HPMC-based formulation Fii (Fig. 7A). These data indicated that the
improved release rate of biochanin A from films Faa and Fjj was due to the
presence of biochanin A in noncrystalline, amorphous state in these films. This
was also in agreement with the visualization and dissolution data (Fig. 5 and
Fig. 6).
To further address this question, differential scanning calorimetry (DSC)
experiments were carried out. Thermograms of the pure biochanin A powder
showed a melting endothermic event at 212 C˚, while none of the biochanin A
containing films showed any melting events for biochanin A (Fig. 7B). Also in the
case of formulation Fii and physical mixture of formulation Faa components, no
indication of crystalline form of biochanin A was seen in the thermograms even
though X-ray diffractograms indicated its crystallinity. Probably, softening of the
polymer at elevated temperature and presence of propylenglycol were responsible
for dissolution of biochanin A in the formulations before its melting point.
Discussion
Rather than as a bacteriocidal or bacteriostatic agent, biochanin A has been
discussed as a potentiator of other antimicrobial agents. Biochanin A, as well as
two other isoflavones genistein and orobol, have been reported to potentiate the
antibacterial activities of norfloxacin and a natural plant antibiotic berberine
against Staphylococcus aureus at concentration of 6.25 mg/l (approximately
22 mM), but none of these three isoflavones as such suppressed S. aureus growth
even at the highest concentration tested (100 mg/l; approximately 350 mM) [36].
Similar behavior has also been reported against Mycobacterium smegmatis:
biochanin A had a MIC value of 256 mg/l (approximately 900 mM) for growth
inhibition, but was able to potentiate the antimycobacterial effects of other
chemical agents at significantly lower concentrations (10–32 mg/l, i.e. 35–
110 mM, respectively) [37]. Based on mechanistical studies, such potentiating
effects have been linked to inhibition of bacterial multidrug resistance (MDR)
efflux pump functions by biochanin A.
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Fig. 7. X-ray diffraction and DSC measurements of film formulations. A) X-ray diffraction patterns of (a)
biochanin A powder, (b) genistein powder, (c) HPMC powder, (d) film Fii, (e) blank film Faa without biochanin
A, (f) film Faa, (g) film Fjj and (h) physical mixture of formulation Faa. B) DSC thermograms of (a) biochanin A
powder, (b) HPMC powder, (c) film Fii, (d) blank film Faa without biochanin A, (e) film Faa, (f) film Fjj and (g)
physical mixture of formulation Faa.
doi:10.1371/journal.pone.0115115.g007
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The results presented in the current work demonstrate that besides its
potentiating effects on other antibacterial compounds, biochanin A directly
inhibits the growth of Gram-negative intracellular bacteria in genus Chlamydia.
According to our data, it completely prevents the formation of C. pneumoniae
inclusions at concentrations of 25 mM or higher and significantly decreases the
inclusion counts at low micromolar concentrations. It also prevents the formation
of new infectious progeny, which is seen as the lack of infectivity of the collected
progeny upon new infection cycle. Furthermore, treatment of the C. trachomatis
infected cell cultures with biochanin A significantly suppresses inclusion counts
and decreases the mean bacterial inclusion size.
The current work represents to our knowledge the first report of biochanin A or
other isoflavones as direct growth inhibitors of Gram-negative bacteria. The
success rates of discovering antibacterial compounds from plants are typically
significantly lower than from microbial sources, and identification of plant-
derived compounds active against Gram-negative bacteria has been particularly
challenging [38]. Given the atypical nature of plant derived compounds as
antibacterial agents and the essential contribution of host cell metabolism to the
intracellular replication process of Chlamydia, it is not clear whether the
antichlamydial activities of isoflavones are mediated through a bacterial target or
via modulation of the host cell in a manner unfavorable to the bacterium.
Pretreatment experiments demonstrated that biochanin A does not affect C.
pneumoniae in its extracellular (EB) form but the fundamental changes in
chlamydial morphology and metabolism upon its entry to a host cell offer a
spectrum of possible targets for growth inhibition. Considering host cell targets,
any effects on host cell protein expression can be ruled out due to the presence of
cycloheximide in the infection medium. Potential targets are thereby limited to
the bacterium itself or a host cells component present at the time of inoculation.
Besides its affinity to bacterial efflux pumps, biochanin A has been shown to
block also p-glycoprotein, the major MDR efflux pump in mammalian cells which
is structurally unrelated to the bacterial efflux pumps. Altered p-glycoprotein
substrate drug transport and bioavailability upon coadministration with
biochanin A has been reported both in vitro and in vivo [39, 40]. Chemical
inhibition of MDR1 was recently shown to restore the antibiotic susceptibility of
C. trachomatis in hypoxic conditions, but the MDR1 inhibitor cyclosporine A
used in the study did not have any significant effect on C. trachomatis growth
when used alone [41]. These findings further support the view that the affinity of
biochanin A to bacterial and mammalian efflux pumps may be an additional
beneficial feature for the antibacterial applications with this compound although
in the light of the current evidence it is not the main mechanism of action for the
direct antichlamydial effects.
In our earlier studies, we have identified several other flavonoids as C.
pneumoniae growth inhibitors [23, 25]. The small structure-activity relationship
analysis conducted in this work confirms our earlier observations on the
importance of 5,7-dihydroxyl substitutions for efficient anti-C. pneumoniae
activity. However, biochanin A differs from the earlier identified highly active
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antichlamydial flavonoids by its isoflavone structure. Furthermore, the current
work expands the antichlamydial activities of isoflavones to cover also C.
trachomatis. C. pneumoniae and C. trachomatis are both human pathogens but
they differ significantly in their tissue tropism and diseases they are able to cause.
The degree of functional conservation between C. pneumoniae and C. trachomatis
is relatively high and especially the functions related to transcription and
metabolism are well conserved between the two species. However, comparative
analysis of the genetic sequences of these two bacterial species has revealed also
essential differences between the two species [42], which is also evident within the
differences in antibiotic susceptibility between C. trachomatis and C. pneumoniae
[43]
Due to the interest in isoflavones as phytoestrogens, a significant body of
information is available on their pharmacokinetic properties. In healthy adults,
peak plasma concentrations are typically reached within 5–9 h after ingestion [6].
The efficiency of intestinal absorption is, however, limited by the extensive first
pass metabolism and recycling. As discussed earlier, majority of biochanin A is
converted to genistein prior to its absorption via demethylation reactions and less
than 5% of biochanin A in bloodstream is found in its parent methylated form
after ingestion of the pure compound.
Given these challenges in oral bioavailability and the weaker antichlamydial
activity of genistein compared to biochanin A, buccal route of administration was
studied as an alternative means for delivering biochanin A into the body.
Although data with Caco-2 cells and in perfused intestine models show that
biochanin A is permeable through intestinal membranes [9], buccal mucosa is
known to possess properties different from intestinal wall in regards of epithelial
cell organization, lipid composition and biotransformation [44]. The permeability
studies carried out with porcine buccal mucosa demonstrated that biochanin A is
able to penetrate buccal mucosa and conversion of biochanin A to genistein was
not observed during the process. Similar results were obtained from the
preliminary permeation studies of biochanin A released from Fjj films in Franz
diffusion cell setup.
Permeation of biochanin A across the buccal mucosa was dependent on the
concentration of the dissolved drug since the concentration difference between
two sides of the mucosa serves as driving force for drug diffusion. Thus an
increase in the concentration of the dissolved biochanin A would provide higher
flux leading to faster permeation. It is obvious that the formulated films provided
faster dissolution rates, while the solubility of the biochanin A in water however
remains the same, leading to permeation rate to remain constant. Based on these
observations, it was concluded that the rate-limiting step on biochanin A buccal
bioavailability was permeation rather than dissolution. While addition of a
permeation enhancer into the film formulation might thus allow full exploitation
of the increased dissolution rate of biochanin A, these data demonstrate that
biochanin A can be absorbed via buccal route without conversion to genistein or
other metabolites.
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Drug delivery by means of oral films is a rapidly growing research and
marketing area [34, 35, 45–49]. The advantages of the thin films made of water
soluble polymers can include, among other things, improved bioavailability of
poorly soluble drugs, reduction in the dose and drug entrance of the systemic
circulation without undergoing first-pass metabolism. These features make this
type of the delivery system potentially feasible for developing the biochanin A
containing formulation to maximize compound’s effect on the bacteria and
minimize its dose.
Oromucosal film preparations provide a feasible route of administration for
biochanin A. During our dissolution studies, we observed significant differences
in dissolution rates between the formulations. The film containing hydroxypropyl
cellulose as a film-forming polymer, Tween 20 as a solubilizer, and maize starch as
a disintegrant was found to show the fastest release profile. Thus, maize starch was
found to work better than the two tested superdisintegrants. In the case of
crospovidone, disintegration of the formulation occurs by capillary action and
hydration [50], whereas pronounced swelling occurs when sodium starch
glycolate is used [51].
The in vitro dissolution studies showed that by film formulations, a significant
improvement of the dissolution rate of biochanin A was achieved without the
need for chemical modifications of the active ingredient. Characterization of the
formulations indicated that increased dissolution rate was achieved due to the
solubilizing effect of the hydrophilic additives and by the presence of biochanin A
in amorphous state in the formulation. This finding is also supported by another
recent report on the preparation of solid dispersions with amorphous biochanin
A, using hydrophilic polymers Solutol HS 15 and HPMC 2915 [8]. With these
formulations intended for conventional oral administration, the bioavailability
was improved by 8- to 60-folds in comparison to unmodified biochanin A
powder. However, ethanol - dichloromethane mixture of 1:1 was used as a solvent
to dissolve biochanin A and the ethanol-insoluble HPMC. Due to toxicity of
dichloromethane, its use during preparation of solid dosage forms is undesirable
and thus the HPC-based formulation used in this study, requiring only ethanol, is
a more attractive alternative, and the buccal administration route optimally
provides added value to administration of the antibacterial compound through
the avoidance of first-pass metabolism.
In summary, the current work demonstrates that biochanin A is a potent
inhibitor of the intracellular gram-negative bacteria Chlamydia pneumoniae and
C. trachomatis. According to our cell viability assay results, it shows no harmful
effects on the host cell viability and the safety of biochanin A for human use is
supported also by the routine intake of biochanin A and related isoflavones in
foods and dietary supplements. The formulated films showed significantly
improved dissolution rate of biochanin A compared to the powder or a physical
mixture, presumably due to the solubilizing effect of the hydrophilic additives and
presence of biochanin A in the amorphous state. Biochanin A was released from
film formulation and could permeate porcine buccal tissue without changing to
genistein. From a natural product drug discovery perspective, these data open new
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alternatives for improving the bioavailability of similar compounds without the
need for chemical modifications, which often affect the desired biological activity.
Supporting Information
S1 Figure. Simultaneous thermal analysis (STA) of biochanin A and genistein
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S1 Table. HPLC analysis of biochanin A and genistein powder and formulation
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